TransSerum? RQ Fetal Bovine Serum
胎牛血清（優(yōu)級）
| 目錄號 | 規(guī)格 | 單價 |
|---|---|---|
| FS401-02 | 500 ml | 詢價 |
產(chǎn)品詳情介紹
本產(chǎn)品以健康胎牛血液為原料加工而成，經(jīng)3次0.1 μm微孔濾膜過濾，無支原體污染，不含BVDV、BPV等牛源病毒，內(nèi)毒素水平低，適用于各種傳代細胞、腫瘤細胞的培養(yǎng)，是一款通用性強的經(jīng)濟型胎牛血清。
【雜交瘤細胞專項型】專項優(yōu)化配方，致力于賦能雜交瘤細胞快速增殖與高效抗體生產(chǎn)。
應用范圍
適用于雜交瘤細胞、各種傳代細胞、腫瘤細胞的培養(yǎng)
TransSerum? RQ Fetal Bovine Serum成功培養(yǎng)的細胞
產(chǎn)品性能
細胞培養(yǎng)
配制含有 10% RQ血清的生長培養(yǎng)基，培養(yǎng)不同類型的細胞，對其進行傳代，在顯微鏡下觀察每一代細胞的形態(tài)。
TransSerum? RQ血清培養(yǎng)細胞的下游實驗
用TransIntro? EL Transfection Reagent (FT201) 在不同的轉(zhuǎn)染方式下，對不同細胞轉(zhuǎn)染pLVX-mcherry質(zhì)粒，培養(yǎng)48 h 后，觀察紅色熒光，結(jié)果表明：血清的有無對下游細胞轉(zhuǎn)染實驗基本沒有影響。
1.Wang P, Li H, Zhang X, et al. Microecology in vitro model replicates the human skin microbiome interactions[J]. Nature Communications, 2025.(IF 15.70)
2.Lai P, Miao G, Zhao Y, et al. SR-A3 suppresses AKT activation to protect against MAFLD by inhibiting XIAP-mediated PTEN degradation[J]. Nature Communications, 2025.(IF 15.70)
3.Wang P, Li H, Zhang X, et al. Microecology in vitro model replicates the human skin microbiome interactions[J]. Nature Communications,(IF 15.70)
4.Guo J, Miao G, Zhang W, et al. Depletion of ApoA5 aggravates spontaneous and diet-induced nonalcoholic fatty liver disease by reducing hepatic NR1D1 in hamsters[J]. Theranostics, 2024.(IF 12.40)
5.Wang Z, Cui L, Lin Y, et al. Cancer cell-intrinsic biosynthesis of itaconate promotes tumor immunogenicity[J]. The EMBO Journal, 2024.(IF 9.50)
6.Zhang X, Bhattacharya A, Pu C, et al. A programmable CRISPR/dCas9-based epigenetic editing system enabling loci-targeted histone citrullination and precise transcription regulation[J]. Journal of Genetics and Genomics, 2024,(IF 6.60)
7.Qiao Y, Zhu S, Yang N, et al. The RNA helicase DHX35 functions as a co-sensor for RIG-I-mediated innate immunity[J]. PLoS Pathogens, 2024.(IF 5.50)
8.He H, Lv C, Xie Y, et al. Carnosine alleviates oxidative stress to prevent cellular senescence by regulating Nrf2/HO-1 pathway: a promising anti-aging strategy for oral mucosa[J]. Frontiers in Pharmacology, 2025,(IF 4.80)
